Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | SCN1A | P35498 | 2/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456910 | 0.78 | POLB (0.40) | BCHESCN1ASCN2ASCN3ACHRM5 | |
| SCHEMBL21614352 | 0.73 | OPRL1 (0.38) | BCHECHRM5CHRM1CHRM3MEN1 | |
| SCHEMBL29213787 | 0.71 | CHRM4 (0.38) | BCHECHRM4MEN1KMT2AALDH1A1 | |
| SCHEMBL29213800 | 0.71 | BCHE (0.45) | BCHESCN1ASCN2ASCN3A | |
| SCHEMBL29213856 | 0.70 | DRD2 (0.46) | BCHE | |
| SCHEMBL16635210 | 0.69 | SMN1; SMN2 (0.60) | MEN1KMT2A | |
| SCHEMBL31751694 | 0.68 | SMN1; SMN2 (0.57) | MEN1KMT2A | |
| SCHEMBL20113192 | 0.68 | BCHE (0.45) | BCHEMEN1KMT2AALDH1A1 | |
| SCHEMBL29213786 | 0.67 | L3MBTL3 (0.39) | CHRM4MEN1KMT2AALDH1A1 | |
| SCHEMBL29213831 | 0.66 | CHRM4 (0.41) | CHRM4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180291014-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291014-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | BCHE 2913/4885SCN1A 991/4885SCN2A 1827/4885 |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | BCHE 2913/4885SCN1A 991/4885SCN2A 1827/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | BCHE 2913/4885SCN1A 991/4885SCN2A 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.